Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Quantitative Phase Technology Using Silicon Designed to Visualize Cellular Processes

By BiotechDaily International staff writers
Posted on 16 Oct 2013
A team of scientists has figured out how to quantitatively observe cellular processes taking place on “lab-on-a-chip” devices in a silicon setting.

The new technology should be useful in drug development as well as disease diagnosis, researchers working on the project. In a study published October 2, 2013, in Nature’s online journal Scientific Reports, the investigators reported that it overcame past limitations on quantitative microscopy through an opaque media by working with a new combination of near infrared light and a technique called quantitative phase imaging. The technology is approximately 10-years old and uses shifts in phases of light, not staining techniques, to aid specimen imaging—warranting the term “label-free.”

“To the best of our knowledge, this is the first demonstration of quantitative phase imaging of cellular structure and function in silicon environment,” said Assistant Professor of physics Dr. Samarendra Mohanty, head of the biophysics and physiology laboratory at University of Texas (UT) at Arlington (USA), and corresponding author of the article.

The UT at Arlington and Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) group of scientists was able to study specimens through a silicon wafer in two cases. In one, they achieved full-field imaging of the features of red blood cells to nanometer thickness accuracy. They observed, in another specimen, the dynamic variation of human embryonic kidney cells in response to variations in salt concentration. Dr. Mohanty believes that his group’s current research on near-infrared quantitative-phase imaging can lead to noninvasive, label-free monitoring of neuronal activities.

“Silicon-based microdevices known as labs-on-a-chip are revolutionizing high throughput analysis of cells and molecules for disease diagnosis and screening of drug effects. However, very little progress has been made in the optical characterization of samples in these systems,” said Dr. Bipin Joshi, a recent graduate and lead author of the study. “The technology we’ve developed is well-suited to meet this need.”

Dr. Barman, now an assistant professor at Johns Hopkins University (Baltimore, MD, USA), stated that this study is an excellent example of the type of research he envisages doing, projects driven by needs of the biomedical community and continually pushing the edge of biophotonic technology. “We envision that this significantly expands the visualization possible in silicon based microelectronic and micromechanical devices,” he said.

Related Links:
University of Texas at Arlington
Massachusetts Institute of Technology



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.